» Articles » PMID: 11585736

Suppression of Intestinal and Mammary Neoplasia by Lifetime Administration of Aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) Mice

Overview
Journal Cancer Res
Specialty Oncology
Date 2001 Oct 5
PMID 11585736
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Numerous studies have indicated that exposure to nonsteroidal anti-inflammatory drugs is associated with a lowered risk of colorectal cancer. However, analyses of the effect of aspirin upon tumorigenesis in Apc(Min/+) mice have yielded contrasting results. We show that adult dietary exposure to aspirin does not suppress intestinal tumorigenesis in Apc(Min/+) mice, but that continual exposure from the point of conception does. To test whether this regime could suppress the phenotype of murine models of hereditary nonpolyposis colorectal cancer, Msh2-deficient mice were exposed to aspirin. This did not modify the mutator phenotype of Msh2(-/-) mice, but weakly extended survival. Finally, we analyzed (Apc(Min/+), Msh2(-/-)) mice and found that lifetime aspirin exposure significantly delayed the onset of both intestinal and mammary neoplasia. Thus embryonic and perinatal exposure to aspirin suppresses neoplasia specifically associated with the loss of Apc function, opening a potential window of opportunity for nonsteroidal anti-inflammatory drug intervention.

Citing Articles

Nrf2 activation does not affect adenoma development in a mouse model of colorectal cancer.

Knatko E, Castro C, Higgins M, Zhang Y, Honda T, Henderson C Commun Biol. 2021; 4(1):1081.

PMID: 34526660 PMC: 8443638. DOI: 10.1038/s42003-021-02552-w.


Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum.

Brennan C, Nakatsu G, Gallini Comeau C, Drew D, Glickman J, Schoen R mBio. 2021; 12(2).

PMID: 33824205 PMC: 8092249. DOI: 10.1128/mBio.00547-21.


Aspirin in the Prevention of Colorectal Neoplasia.

Drew D, Chan A Annu Rev Med. 2020; 72:415-430.

PMID: 33035431 PMC: 7880546. DOI: 10.1146/annurev-med-060319-120913.


Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development.

Davis J, Kanikarla-Marie P, Gagea M, Yu P, Fang D, Sebastian M BMC Cancer. 2020; 20(1):871.

PMID: 32912193 PMC: 7488444. DOI: 10.1186/s12885-020-07311-4.


Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.

Rohwer N, Kuhl A, Ostermann A, Hartung N, Schebb N, Zopf D Cancer Med. 2020; 9(7):2535-2550.

PMID: 31994315 PMC: 7131863. DOI: 10.1002/cam4.2881.